Skip to main content

Advertisement

Table 1 Patient and treatment parameters

From: Safety of high-dose-rate stereotactic body radiotherapy

  N 1
Gender
 Male 48 (57%)
 Female 36 (43%)
Age
 Mean/Median [years] 66/67
 Range [years] 19 - 88
RT localization
 Lung 75 (75%)
 Liver 10 (10%)
 Adrenal gland 6 (6%)
 Lymph node 5 (5%)
 Other site 4 (4%)
Lesions treated
 Primary tumor 25 (25%)
 Metastasis 45 (45%)
 Tumor recurrence 16 (16%)
 Primary tumor/Metastasis 14 (14%)
Prescription dose
 48 Gy/4 fx 19 (19%)
 40 Gy/4 fx 10 (10%)
 35 Gy/5 fx 6 (6%)
 60 Gy/10 fx 5 (5%)
 50 Gy/10 fx 5 (5%)
 Other 55 (55%)
BED
 <100 Gy 66 (66%)
 ≥100 Gy 34 (34%)
GTV size
 Mean [cm3]/Median [cm3] 15.4/6.7
 Range [cm3] 0.60 - 126.7
 <14 cm3 65 (65%)
 ≥14 cm3 35 (35%)
PTV size
 Mean [cm3]/Median [cm3] 58.2/35.2
 Range [cm3] 5.9 - 368.7
Energy
 6 MV 84 (84%)
 10 MV 16 (16%)
Dose rate
 Mean [MU/min.]/Median [MU/min.] 1319/1400
 Range [MU/min] 451 - 2400
  1. N1 = number of patients or lesions if not indicated otherwise. (RT: Radiation Therapy, fx: fractions, BED: Biologically Effective Dose, GTV: Gross Tumor Volume, PTV: Planning Target Volume, MU: Monitor Unit).